Major trial tests promising new treatment for Tough-to-Treat lung cancer
NCT ID NCT05690945
Summary
This large Phase 3 trial is comparing a new drug combination (QL1706 plus chemotherapy) against a standard treatment for patients with advanced non-small cell lung cancer that has spread and tests negative for a specific biomarker called PD-L1. The study aims to see if the new combination helps patients live longer or better controls their cancer compared to current options. About 606 participants were randomly assigned to receive either the experimental treatment or the standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.